Teva's pay-for-delay probe could wrap up next year, EU official says
Teva could learn next year whether its alleged agreement with Cephalon not to market a cheaper generic version of sleep-disorder drug modafinil breaches EU competition rules, an official said today. This...To view the full article, register now.
Already a subscriber? Click here to view full article